Fertility and Sterility, 6(1), 18-36, 1954
Study of the inadequate secretion phase endometrium
Author affiliations
- Wells Fargo (United States) ROR
Abstract not indexed. Read at publisher
Topics
inadequate secretory phase endometrium infertility, luteal phase defect endometrial biopsy 1950s, Gillam inadequate secretion phase endometrium study, endometrial maturation defect corpus luteum insufficiency, secretory phase endometrium histological evaluation, luteal phase deficiency endometrial dating, progesterone insufficiency endometrial development, endometrial biopsy luteal phase defect diagnosis, inadequate luteal phase histopathology fertility, secretory endometrium abnormalities recurrent pregnancy loss
PMID 13220643 13220643 DOI 10.1016/s0015-0282(16)31862-3 10.1016/s0015-0282(16)31862-3
Cite this article
Gillam, J. S. (1954). Study of the inadequate secretion phase endometrium. Fertility and Sterility, 6(1), 18-36. https://doi.org/10.1016/s0015-0282(16)31862-3
Gillam JS. Study of the inadequate secretion phase endometrium. Fertil Steril. 1954;6(1):18-36. doi:10.1016/s0015-0282(16)31862-3
Gillam, John s. "Study of the inadequate secretion phase endometrium." Fertility and Sterility, vol. 6, no. 1, 1954, pp. 18-36.
Keywords
Disease, Endometrium, Female, Humans, Infertility, Infertility, Female/etiology, Progesterone/therapeutic Use, Uterine Diseases, Progesterone, ENDOMETRIUM/diseases, PROGESTERONE/therapeutic Use, STERILITY, FEMALE/etiology and Pathogenesis
Related articles
Reproductive EndocrinologyVaginal Administration PharmacokineticsEndometrial EffectsEndometrial Preparation
Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study
Miles RA et al., 1994·Fertil Steril
To determine pharmacokinetic and endometrial effects of vaginally delivered micronized P. Functionally agonadal estrogen-replacement recipients received either micronized P administered vaginally or bi-daily IM injections of P. Hourly blood samples were obtained, from baseline to 6 hours after the initial dose of P and again on simulated cycle day 21 when transvaginal ultrasound (US) measurements and tissue samples of the endometrium were performed. Blood and tissue samples were assayed for P. Endometrial histology, estrogen receptor (ER) and P receptor (PR) contents were evaluated. University of Southern California School of Medicine, Los Angeles, California. Twenty functionally agonadal and four normally ovulating women. Delivery differences were assessed by [1] endometrial P concentrations; [2] USs; [3] histologic datings; [4] ER and PR contents, and [5] serum P levels. Endometrial P concentrations were higher with vaginally administered P than endometrial concentrations observed in normal ovulatory women or women who consistently had the highest serum P after IM administration (11.50 +/- 2.60 versus 1.40 +/- 0.40 versus 0.30 +/- 0.10 ng/mg protein [36.56 +/- 8.27 versus 4.45 +/- 1.27 versus 0.95 +/- 0.32 nmol/L], respectively). After 7 days of P, no differences between either treatment regimen and control groups were detected by histologic, ultrasonographic, or immunocytochemical receptor analyses. Vaginal micronized P enhances P delivery to the uterus compared with a standard IM regimen and results in a synchronous secretory endometrial histology in agonadal women preparing for embryo donation.
Reproductive EndocrinologyEndometrial EffectsGene ExpressionMifepristone Mechanisms
Progesterone supplementation after postovulatory mifepristone reduce changes in human endometrial gene expression
Tapia-Pizarro A et al., 2025·Reproduction
Progesterone supplementation reverses 83% of transcript changes in the secretory endometrium induced by postovulatory mifepristone, potentially mitigating its antiprogestogenic effects. Mifepristone (RU486) antagonizes progesterone signaling in human endometrium interfering in the secretory phenotype after estradiol priming. The objective of the present study was to determine effect in the endometrial transcript profile of progesterone supplementation after the administration of 200 mg of the antiprogestin mifepristone 48 h after the LH peak (LH+2, LH+0 = LH peak). Endometrial samples were obtained on LH+7 after vaginal administration of micronized progesterone 200 mg/day for 3 days in nine women of proven fertility, each one contributing with one cycle treated with progesterone and another with a placebo. In addition, endometrial samples were obtained in LH+7 from a subgroup of four women with no administration of mifepristone, with each one contributing with one cycle treated with vaginal progesterone supplementation or placebo as a reference. RNA-seq was used to identify transcripts significantly regulated under the administration of progesterone vs placebo with or without postovulatory mifepristone. We observed that 713 transcripts changed significantly in the endometrium under mifepristone after progesterone supplementation in group A. Of these, progesterone reversed approximately 83% of the transcripts affected by mifepristone in the secretory endometrium. Bioinformatic analyses revealed that these transcripts were enriched in genes associated with mitochondrial function, particularly oxidative phosphorylation. In addition, NR2C2 and DLX1 were identified as potential transcription factors that may mediate the effects of progesterone in the endometrium. We conclude that progesterone supplementation after postovulatory mifepristone administration can reverse the antiprogestogenic effects for most of the affected endometrial transcripts.
Menstrual CycleEndometrial InflammationEndometrial EffectsTissue Breakdown and Repair
Inflammation, leukocytes and menstruation
Evans J et al., 2012·Rev Endocr Metab Disord
Menstruation has many of the features of an inflammatory process. The complexity and sequence of inflammatory-type events leading to the final tissue breakdown and bleeding are slowly being unravelled. Progesterone has anti-inflammatory properties, and its rapidly declining levels (along with those of estrogen) in the late secretory phase of each non-conception cycle, initiates a sequence of interdependent events of an inflammatory nature involving local inter-cellular interactions within the endometrium. Intracellular responses to loss of progesterone (in decidualized stromal, vascular and epithelial cells) lead to decreased prostaglandin metabolism and loss of protection from reactive oxygen species (ROS). Increased ROS results in release of NFκB from suppression with activation of target gene transcription and increased synthesis of pro-inflammatory prostaglandins, cytokines, chemokines and matrix metalloproteinases (MMP). The resultant leukocyte recruitment, with changing phenotypes and activation, provide further degradative enzymes and MMP activators, which together with a hypoxic environment induced by prostaglandin actions, lead to the tissue breakdown and bleeding characteristic of menstruation. In parallel, at sites where shedding is complete, microenvironmentally-induced changes in phenotypes of neutrophils and macrophages from proto anti-inflammatory, in addition to induction of growth factors, contribute to the very rapid re-epithelialization and restoration of tissue integrity.
EndometriosisLuteal Phase DefectsLuteal Phase DeficiencyMechanisms
Luteal phase defects in infertility patients with endometriosis
Pittaway DE et al., 1983·Fertil Steril
The cause of infertility has remained obscure in women with endometriosis in whom the tuboovarian relationship is unaltered. Abnormal corpus luteum function has been one mechanism implicated in the pathophysiology of endometriosis in infertilityl-3 and may also be a possible explanation for the high frequency of spontaneous abortions among women with untreated endometriosis.4 However, we have observed only an occasional occurrence of luteal phase deficiency in women with an ultimate diagnosis of endometriosis. In order to verify this observation, we examined the incidence of luteal phase defects (LPDs) in. our infertility population.